Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells.
Patients with recurrent malignant brain cancer, who were receiving gene therapy by intracerebral injection of murine retroviral vector producer cells (VPCs), were monitored for the presence of replication-competent retrovirus (RCR). RCR sequences were not detected by polymerase chain reaction (PCR) in any of the 608 peripheral blood leukocyte (PBL) samples analyzed. Vector DNA sequences were detected transiently in PBL samples from a subset of 34 patients. Humoral immune responses to a retroviral core protein p30 and murine VPC were detected in some patients, most frequently in patients receiving repeated administrations of VPC. RCR was not detected in biological assays of PBLs from 41 patients who had either anti-retroviral antibodies in sera and/or vector DNA in PBLs. Our data suggest that in situ generation of RCR was not detected following intracerebral inoculation of VPCs in any of the 128 patients evaluated.
Long
Z
Z
Genetic Therapy, Inc., Gaithersburg, MD 20878, USA.
Li
L P
LP
Grooms
T
T
Lockey
C
C
Nader
K
K
Mychkovsky
I
I
Mueller
S
S
Burimski
I
I
Ryan
P
P
Kikuchi
G
G
Ennist
D
D
Marcus
S
S
Otto
E
E
McGarrity
G
G
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001932:Brain Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008845:Microinjections; D008991:Monitoring, Physiologic / Q000379:methods*; D015337:Multicenter Studies as Topic; D016133:Polymerase Chain Reaction; D012190:Retroviridae / Q000235:genetics*; D014481:United States; D014486:United States Food and Drug Administration; D014779:Virus Replication
D000914:Antibodies, Viral